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Abstract
Background: This study investigates differences in depression and anxiety between patients with chronic hepatitis
C who are treated with peginterferon alpha-2a (PegIFN-α-2a) plus ribavirin and those who are treated with
peginterferon alpha-2b (PegIFN-α-2b) plus ribavirin.
Methods: In this 24 week, non-randomized, observational, prospective study, 55 patients with chronic hepatitis C
were treated with PegIFN-α-2a plus ribavirin (Group 1), and 26 patients were treated with PegIFN-α-2b plus ribavirin
(Group 2). All patients underwent assessment using the Hospital Anxiety and Depression Scale (HADS) at the
baseline and at weeks 4, 12 and 24. Patients with depression scores (HADS-D) ≥ 8 and anxiety scores (HADS-A) ≥ 8
were defined as having depression and anxiety, respectively. The factors that were associated with depression and
anxiety during the 24 week antiviral treatment were determined.
Results: During the 24 week antiviral treatment, the proportion of patients with depression significantly increased
over time in both groups (Group 1: p = 0.048; Group 2: p = 0.044). The proportion of patients with anxiety did not
significantly change during the follow-up period in either group. Incidences of depression or anxiety did not differ
significantly between Group 1 and Group 2. A history of alcohol use disorder was an independent predictor of
depression at week 12 (p < 0.001) and week 24 (p < 0.001), and a poor virological response to treatment was
associated with depression at week 24 (p = 0.029). Patients who had more physical comorbidities were more likely
to suffer from anxiety at week 12 (p = 0.038).
Conclusions: This study did not identify significant differences in depression or anxiety between in patients with
chronic hepatitis C who underwent a 24 week antiviral treatment regimen with PegIFN-α-2a plus ribavirin and
those who underwent a regiment with PegIFN-α-2b plus ribavirin. Future research with larger samples and a
randomized, controlled design are required to verify the findings in this study.
Trial registration: This clinical study has been registered at ClinicalTrials.gov. (Trial registration: NCT02943330).
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Background
Chronic infection with hepatitis C virus (HCV) is a
serious health problem worldwide. Chronic hepatitis
C increases the risk of morbidity and mortality from
sequelae such as liver cirrhosis and hepatocellular
carcinoma [1]. The purpose of treatment is the
prevention of complications of chronic HCV infec-
tion, which is principally achieved by eradicating the
infection [2]. A combination of weekly subcutaneous
injections of long-acting peginterferon alfa (PegIFN-α)
and oral ribavirin greatly improves the efficacy of
antiviral treatment and represents the current stand-
ard of care for patients with chronic hepatitis C [2].
Depression is one of the most common neuropsychi-
atric complications during antiviral treatment for
chronic hepatitis C [3–7]. A meta-analysis has found
that around 25% of chronic hepatitis C patients who
receive interferon and ribavirin treatment will develop
a treatment-induced major depressive episode [6].
Although interferon exposure is clearly associated
with an increased incidence of depression, the rela-
tionships of the frequency and magnitude of depres-
sion with the specific type of interferon used have
seldom been evaluated [5].
The two available licensed products of PegIFN-α are
peginterferon alfa-2a (PegIFN-α-2a) and peginterferon
alfa-2b (PegIFN-α-2b), which differ in their pharmaco-
kinetics and chemical properties; both are cost-effective
and recommended for use in combination with ribavirin
for treating chronic hepatitis C [8]. Several researchers
have found that, when combined with ribavirin (RBV),
PegIFN-α-2a yields a higher virological response rate
than does PegIFN-α-2b, [9, 10]. However, one review
article indicated that PegIFN-α-2a and PegIFN-α-2b ex-
hibit similar degrees of effectiveness and tolerability,
with few clinical differences [11], while investigations
have suggested similar sustained virological response
(SVR) rates and frequencies of adverse events upon
treatment with PegIFN-α-2a to those with -2b [11–13].
Compared to those treated with PegIFN-α-2a plus RBV,
some clinical trials have indicated that patients treated
with PegIFN-α-2b plus RBV have similar incidence rates
of depression [14, 15], whereas one revealed that pa-
tients administrated with PegIFN-α-2b plus RBV have
higher probability of depression [16]. To date, no con-
clusive evidence has established that one PegIFN-α is su-
perior to the other, or that one type of PegIFN-α is more
likely to induce depression than the other when com-
bined with RBV in the treatment of chronic hepatitis C.
This study investigates the differences in depression
and anxiety between patients with hepatitis C who
receive PegIFN-α-2a plus RBV and those who receive
PegIFN-α-2b plus RBV. The factors that are associated
with depression and anxiety are examined.
Methods
Participants and procedures
The study was conducted according to the ethical guide-
lines of the Good Clinical Practice and was approved by
the Institutional Review Board of Chang Gung Memorial
Hospital. Each patient who was enrolled in this study
gave written informed consent. This clinical study has
been retrospectively registered at ClinicalTrials.gov.
(Trial registration: NCT02943330).
In this prospective study, 81 patients who were
diagnosed with hepatitis C (aged ≥18 years) and received
PegIFN plus RBV combination therapy were enrolled at
Keelung Chang Gung Memorial Hospital (the largest
general hospital in North-East Taiwan). All 81 patients
received a 24-week combination treatment with a weekly
subcutaneous PegIFN injection plus daily oral RBV. The
treatment regimen is consistent with the reimbursement
criteria of the National Health Insurance in Taiwan. The
prescribed PegIFN regimen was either 180 μg of
PegIFN-α-2a, or 1.5 μg/kg (weight-based) PegIFN-α-2b.
The treatment regimens were allocated by the physi-
cians’ decision, based on patients’ body weight and
clinical manifestations. In cases of genotype 1 HCV
infection, the oral RBV dose was 1000 mg daily for
patients with body weight (BW) <75 kg or 1200 mg for
those with BW ≥75 kg. If genotype non-1 HCV-
infection, the RBV dose was 800 mg daily. After the end
of the treatment, all patients were followed up for
24 weeks.
In the treatment period, patients made weekly out-
patient visits for the first four weeks, biweekly visits
between the fifth and 12th weeks, and monthly visits for
the last 12 weeks. During the 24 week follow-up period,
patients attended the clinic monthly or bimonthly. Hep-
atic biochemical tests were performed on each visit.
HCV RNA levels were measured at the beginning of
treatment, the end of treatment and 24 weeks after treat-
ment. All biochemical and virological tests were carried
out in the clinical laboratories of Chang Gung Memorial
Hospital at Keelung. Adverse effects of antiviral treat-
ment were recorded at each visit. Of all enrolled pa-
tients, 55 received combination treatment with PegIFN-
α-2a plus RBV (Group 1), and 26 received combination
treatment with PegIFN-α-2b plus RBV (Group 2).
This study was a 24 week, observational, non-
randomized prospective study. At the baseline (pre-
treatment), patients’ mood-related symptoms were
assessed. Physicians reassessed patients in both groups
at the outpatient department weekly. The second, third
and fourth study assessments were conducted at weeks
4, 12 and 24 after the antiviral treatment had begun.
The assessment of mood-related symptoms at the base-
line was conducted at each time-point in the study
assessments.
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HCV genotyping and treatment response
Anti-HCV tests were carried out using a third-
generation enzyme immunoassay kit (Abbott Laborator-
ies, Berkshire, UK). Quantity of serum HCV RNA was
determined using a real-time polymerase chain reaction
(PCR) assay (Roche Molecular Systems, Inc., Branch-
burg, NJ, USA), with a detection limit of 15 IU/mL.
HCV genotype was identified using a linear probe assay
(Bayer Corporation, NY, USA). The HCV RNA load was
examined before treatment, 4 weeks during treatment,
end of treatment and 24 weeks after treatment. The
treatment efficacy was assessed after 24 weeks of com-
bined PegIFN plus RBV therapy. Patients who were
HCV RNA-negative at week 24 post-treatment follow-
up were regarded as sustained virological response
(SVR).
Evaluation of psychological well-being
Charts were reviewed to collect information about pa-
tients’ alcohol use disorder and comorbid physical ill-
ness. The mood-related symptoms of all patients were
assessed on the Hospital Anxiety and Depression Scale
(HADS) [17]. The HADS is frequently used in hospital
practice and primary care, as well as for the general
population. Of the 14 items, seven items are used to
evaluate anxiety and the rest seven items are used to as-
sess depression. There are four possible responses
(scored 0–3) for each item; the anxiety and depression
subscales are counted as independent measures. A pa-
tient with an anxiety score (HADS-A) ≥ 8 is deemed to
have an anxiety disorder (sensitivity, 0.89; specificity,
0.75) and a patient with a depression score (HADS-D) ≥
8 is deemed to have a depression disorder (sensitivity,
0.80; specificity, 0.88) [18]. The validation and cut-off
score of Chinese version of the HADS have been re-
ported in previous studies [19, 20].
Statistical analysis
Data analysis was performed using the Statistical Pack-
age for the Social Sciences for Windows (version 16.0;
SPSS, Inc., Chicago, IL, USA). Continuous variables and
categorical variables are presented as either mean ±
standard deviation (SD) and as frequency, respectively.
Categorical variables between Group 1 and Group 2
were examined using either the chi-square (χ2) test or
Fisher’s exact test, depending on case numbers. An inde-
pendent t-test or Mann–Whitney U-test was applied to
compare continuous variables between groups. All statis-
tical tests were two-tailed, and the significant levels were
set as p < 0.05.
The depression and anxiety states of patients were de-
termined using cut-off points of HADS-D (≥8) and
HADS-A (≥8), respectively. The chi-square tests or Fish-
er’s exact tests were carried out to determine whether
the proportion of patients with depression or anxiety
significantly changed over time. The trends of HADS
scores (continuous variable) during the 24 weeks of
treatment were also analyzed. Generalised estimating
equations (GEE) were used to perform a post hoc ana-
lysis of the difference in the depression and anxiety
scores between pairs of time-points and between treat-
ment groups, followed by a post hoc analysis using least
significant difference (LSD) test. To identify the factors
that were associated with depression and anxiety during
combination treatment, GEE, the maximum likelihood
estimation method with an auto-regression covariance
matrix, were used. Degrees of depression and anxiety
were set as dependent variables. Demographic variables,
physical conditions and treatment response were set as
independent variables. Since the attrition rate was high
by week 24, completer analyses were conducted for pa-
tients who remained in the study at week 12 and at week
24, respectively.
Results
This study involved 55 patients with hepatitis C infec-
tion who underwent combination treatment with
PegIFN-α-2a plus RBV (Group 1) and 26 patients who
underwent combination treatment with PegIFN-α-2b
plus ribavirin (Group 2). Table 1 summarizes the base-
line demographic characteristics and mood statuses of
the two patient groups. At the beginning of combination
therapy 14 (25.5%) of patients in Group 1 and 3 (11.5%)
of patients in Group 2 have been classified as depression
cases (HADS-D ≥ 8), and 21 (38.2%) of patients in
Group 1 and 6 (23.1%) of patients in Group 2 have been
classified as anxiety cases (HADS-A ≥ 8). The mean dose
of RBV that was co-administrated for hepatitis C treat-
ment was higher for Group 1 (1048.2 mg/day) than for
Group 2 (958.3 mg/day). There was no significant differ-
ence in other variables.
Of the 55 patients in Group 1, 52 (94.5%), 51 (92.7%)
and 36 (65.5%) remained in the study until weeks 4, 12
and 24, respectively. Of the 26 patients in Group 2, 22
(84.6%), 19 (73.1%) and 15 (57.7%) remained in the study
until weeks 4, 12 and 24, respectively. After six months
of treatment, 22 (61.1%) patients in Group 1 and nine
(60%) patients in Group 2, respectively, were SVR (HCV
RNA-negative). The attrition rates (χ2 = 0.46, p = 0.499)
and treatment response (SVR) rates (χ2 = 0.10, p = 0.753)
did not differ significantly between the two groups at the
endpoint.
Figure 1 presents the proportion of patients in the two
groups with depression and anxiety during the 24 week
follow-up. We found the proportion of depression cases
significantly increased in both groups (Group 1: χ2 =
7.89, p = 0.048; Group 2: χ2 = 7.91, p = 0.044). The post
hoc test revealed that the trends of depression in both
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groups (week 12 > baseline; week 24 > baseline) were
similar. The proportion of anxiety cases did not signifi-
cantly change throughout the overall follow-up period in
either group (Group 1: χ2 = 1.01, p = 0.798; Group 2: χ2
= 3.45, p = 0.321). The post hoc test revealed that anxiety
in Group 2 was more prevalent at week 12 than at the
baseline (β = 2.50, p = 0.018). No significant difference
was observed in any other pairwise comparisons be-
tween time-points or the two groups.
The HADS-D scores in both groups significantly in-
creased over time (Group 1: Wald χ2 = 12.78, p = 0.005;
Group 2: Wald χ2 = 9.88, p = 0.020). The post hoc test re-
vealed that the HADS-D scores in Group 1 significantly
increased after week 4 (p < 0.05) while those in Group 2
significantly increased after week 12 (p < 0.05). The
HADS-A scores did not significantly increase over time
in either group (Group 1: Wald χ2 = 3.04, p = 0.385;
Group 2: Wald χ2 = 1.76, p = 0.623). A post hoc test also
revealed that HADS-A scores did not differ significantly
between time-points or groups.
Table 2 lists the factors that were associated with pa-
tients’ depression at week 12 and at 24 week of combin-
ation therapy. Alcohol use disorder was consistently
associated with depression at week 12 (β = 6.59, p <
0.001) and at week 24 (β = 5.96, p < 0.001). Poor re-
sponse to combination therapy (HCV RNA positive) was
significantly associated with patients’ depression at week
24 (β = 2.43, p = 0.029).
Table 3 shows factors that are associated with patients’
anxiety at week 12 and at week 24 of combination treat-
ment. Patients’ physical comorbidities were positively
correlated with their anxiety status at week 12 (β = 1.28,
p = 0.038). Nonetheless, no variable was significantly as-
sociated with anxiety at week 24.
Discussion
During 24 weeks of antiviral treatment, the proportion
of depression cases significantly increased in both
groups over time. Significant differences in depression
or anxiety levels were not observed between patients
with chronic hepatitis C who underwent 24 week anti-
viral treatment with PegIFN-α-2a plus RBV and those
who underwent such treatment with PegIFN-α-2b plus
RBV. A history of alcohol use disorder was an independ-
ent predictor of depression at week 12 and week 24 of
combined PegIFN plus RBV treatment and a poor
Table 1 Baseline characteristics of patients with hepatitis C virus (HCV) infection who were treated with PegIFN-α-2a plus ribavirin
(Group 1) and those who were treated with PegIFN-α-2b plus ribavirin (Group 2)
Characteristics Group 1 (N = 55) Group 2 (N = 26) Statistic Value P-value
Sex (n, %) 0.045 b 0.831
Female 31 (56.4) 14 (53.8)
Male 24 (43.6) 12 (46.2)
Age at recruitment (years) 52.8 ± 12.2 55.0 ± 11.5 0.747 c 0.457
Body weight (kg) 65.7 ± 12.1 63.8 ± 12.8 0.644 c 0.521
Alcohol use disorder (n, %) 7 (12.7) 1 (3.8) 1.564 d 0.426
Number of physical illness 2.8 ± 1.8 2.4 ± 1.2 1.287 c 0.203
α-fetoprotein level (ng/mL) 10.6 ± 15.8 7.6 ± 5.9 0.903 c 0.369
Genotype of HCV a 0.104 b 0.747
1 27 (50) 14 (53.8)
Non-1 27 (50) 12 (46.2)
PegIFN-α-2a dose (mcg/week) 175.1 ± 14.2 - N/A N/A
PegIFN-α-2b dose (mcg/week) - 94.8 ± 12.4 N/A N/A
Ribavirin dose (mg/day) 1048.2 ± 164.5 958.3 ± 131.6 2.357 c 0.021*
HADS-Depression score 5.0 ± 3.8 4.0 ± 3.1 1.008 e 0.314
Depressive state (n, %) 14 (25.5) 3 (11.5) 2.062 d 0.242
HADS-Anxiety score 6.6 ± 4.1 6.7 ± 4.7 0.193 e 0.847
Anxiety state (n, %) 21 (38.2) 6 (23.1) 1.813 b 0.214
Note: Data is expressed by n (%) or mean ± SD
PegIFN-α-2a: Pegylated interferon-α-2a, PegIFN-α-2b: Peginterferon-α-2b, HADS: the Hospital Anxiety and Depression Scale, N/A: non-applicable
*p < 0.05
aHCV genotyping of one patient in Group 1 was undetermined
bChi-square test (degrees of freedom = 1)
cFisher’s exact test
dt-test (degrees of freedom = 79)
eMann–Whitney U-test
Wang et al. BMC Psychiatry  (2016) 16:424 Page 4 of 8
virological response to treatment was associated with de-
pression at week 24. Additionally, patients who had
more physical comorbidities were more likely to exhibit
anxiety at week 12.
During the 24 weeks of antiviral treatment, the pro-
portion of patients with depression significantly in-
creased over time, in line with previous reviews and
meta-analysis [5, 6]. Newly developed depression was
observed in 33 patients during antiviral treatment.
Nevertheless, we found that 8 patients whose HADS de-
pression scores were above the cut-off at baseline had
mood improved during treatment. Although the relative
efficacies of different forms of PegIFN-α are currently
debated, the data herein reveal that neither the viro-
logical response rate nor trend in mental health status,
differed between patients who were treated with
PegIFN-α-2a (Group 1) and those who were treatment
with PegIFN-α-2b (Group 2). Notably, this study used
non-randomized and open-label methods. At the base-
line, patients in Group 2 seemed to have a lower anxiety
level, although not significantly, than those in Group 1.
Therefore the possibility of selection bias cannot be ex-
cluded. Randomized trials have revealed that patients
who are given PegIFN-α-2a plus RBV and those who are
given PegIFN-α-2b plus RBV exhibit similar incidences
of depression [14, 15]. However, one trial demonstrated
that patients who were administered PegIFN-α-2b plus
RBV were more likely to develop depression than coun-
terparts who were administered PegIFN-α-2a plus RBV
[16]. Therefore, a future study which conducted in
multi-centre, with randomized controlled design and ad-
equate stratification for controlling the potential con-
founding variables (e.g. mood status at baseline, HCV
genotype, prior psychiatric history) is warranted to de-
termine whether PegIFN-α variants have differently alter
mental health.
Studies have established that relatively many patients
with chronic hepatitis C have alcohol use disorder [21].
Alcohol use disorder is associated with increased use of
illicit substances and impulsive behaviors [22] that may
increase the likelihood of HCV acquisition [23]. Further-
more, alcohol use can worsen hepatic problems and can
lead to a negative effect on adherence to a treatment
regimen and responses to antiviral therapy [23]. This
study revealed that a history of alcohol use disorder pre-
dicted depression during 24 weeks of combination treat-
ment with PegIFN and ribavirin for chronic hepatitis C.
Alcohol abuse can worsen hepatic disease and reduce
adherence to a treatment regimen. Therefore, the identi-
fication and treatment of alcohol abuse in this popula-
tion is very important.
The results of this study indicated that a poor viro-
logical response to combination treatment with inter-
feron and RBV for chronic hepatitis C is associated with
depression at week 24. The possibility of a causal rela-
tionship between the response to antiviral treatment and
depression is intriguing. While treatment with
interferon-α is known potentially to cause neuropsychi-
atric side effects, however, the neuropsychiatric symp-
toms is reduced in HCV patients achieving an SVR [24].
HCV infection is regarded as a systemic disease because
liver disease is accompanied by effects on other organs
and tissues. The brain is a favorable site for HCV repli-
cation, and the virus may be directly neurotoxic. Other
mechanisms that have been proposed to explain the
pathophysiology of neuropsychiatric disorders in cases
of chronic HCV infection, such as derangement in
neurotransmitter circuits, inflammation and auto-
immune dysregulation and alterations of metabolic path-
ways of infected cells. Improvement of neuropsychiatric
symptoms in patients achieving SVR following interferon
Fig. 1 The proportion of depression (a) and anxiety (b) among
patients during a combination treatment with interferon and
ribavirin at the baseline, week 4, 12 and 24. Note: Group 1, patients
who received antiviral treatment with PegIFN-α-2a plus ribavirin;
Group 2, patients who received antiviral treatment with PegIFN-α-2b
plus ribavirin. There were no significant differences in the proportion
of depression or anxiety between the two groups at any time-point.
*p < 0.05 in comparison to the proportion at baseline
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treatment has been noticed [25–28]. Some other factors
may favor depression and the poor outcome of antiviral
treatment. For example, depression is associated with
poor adherence or early discontinuation of antiviral
treatment in cases of chronic hepatitis C [15]. Addition-
ally, patient satisfaction owing to awareness of being
cured of hepatitis C may bias the results of this study.
Therefore, care should be taken in interpreting the asso-
ciation between depression and a poor virological re-
sponse to treatment.
The results herein also demonstrate that the number
of co-morbid physical illnesses was significantly corre-
lated with anxiety at week 12. Previous studies have
found that 24% to 36% of patients who undergo
interferon-α treatment for HCV infection suffer from
anxiety disorders [29, 30]. However, no specific risk fac-
tor for anxiety disorders has been identified [29]. We
propose the possible explanation is patients with many
comorbidities related physical illnesses, not only having
a poorer physical condition, but also suffering from a
greater psychological stress. Patients with multiple phys-
ical comorbidities may be vulnerable to the adverse ef-
fects of PegIFN-α, which are linked to a high probability
of anxiety.
Several limitations of this study should be concerned.
First, the sample size was small - especially in Group 2,
and a smaller sample provides less statistical power to
detect potential differences in mental health between
treatment groups, and limits the ability to assess change
in anxiety score. Second, this study was a naturalistic ob-
servational study, rather than a randomized controlled
trial, hence the results may be influenced by selection
bias. Additionally, the attrition of patients underwent
antiviral treatment could be related to lack of effect,
Table 3 Factors associated with anxiety during an antiviral treatment for hepatitis C virus (HCV) infection at week 12 and at week 24
Characteristics Week 12 Week 24
β (95% CI) Wald χ2 p-value β (95% CI) Wald χ2 p-value
Treatment group (Group 1 vs. Group 2) 1.07 (0.45–2.56) 0.021 0.884 0.88 (0.38–2.02) 0.088 0.767
Sex (female vs. male) 0.89 (0.34–2.35) 0.055 0.815 0.90 (0.38–2.14) 0.059 0.808
Age at recruitment (year) 0.97 (0.94–1.01) 1.911 0.167 0.98 (0.94–1.01) 1.899 0.168
Body weight (kg) 0.99 (0.95–1.02) 0.624 0.430 0.99 (0.95–1.03) 0.326 0.568
Alcohol use disorder 2.07 (0.58–7.42) 1.235 0.266 1.48 (0.46–4.78) 0.430 0.512
Number of physical comorbidities 1.28 (1.01–1.62) 4.303 0.038* 1.21 (0.96–1.53) 2.581 0.108
α-fetoprotein level (ng/mL) 1.00 (0.99–1.02) 0.123 0.726 0.98 (0.94–1.01) 2.403 0.121
Genotype of HCV (non- 1 vs. 1) 0.66 (0.27–1.63) 0.801 0.371 0.70 (0.28–1.72) 0.615 0.433
Ribavirin daily dose (g/day) 1.20 (0.24–6.00) 0.052 0.820 1.95 (0.67–5.64) 1.505 0.220
Poor treatment response (HCV RNA positive) 1.45 (0.60–3.50) 0.669 0.414 1.53 (0.61–3.82) 0.832 0.362
Note: Group 1, patients who were treated with PegIFN-α-2a plus ribavirin; Group 2, patients who were treated with PegIFN-α-2b plus ribavirin; Anxiety, HADS
anxiety score ≥ 8; 95% CI, 95% confidence interval
*p < 0.05
Table 2 Factors associated with depression during an antiviral treatment for hepatitis C virus (HCV) infection at week 12 and at
week 24
Characteristics Week 12 Week 24
β (95% CI) Wald χ2 p-value β (95% CI) Wald χ2 p-value
Treatment group (Group 1 vs. Group 2) 1.33 (0.59–3.00) 0.475 0.490 1.09 (0.51–2.31) 0.046 0.830
Sex (female vs. male) 1.70 (0.69–4.18) 1.335 0.248 1.55 (0.70–3.43) 1.142 0.285
Age at recruitment (year) 0.98 (0.95–1.02) 1.012 0.315 0.99 (0.96–1.02) 0.887 0.346
Body weight (kg) 0.97 (0.94–1.01) 1.956 0.162 0.98 (0.94–1.01) 1.653 0.199
Alcohol use disorder 6.59 (2.31–18.74) 12.474 <0.001** 5.96 (2.21–16.09) 12.424 <0.001**
Number of physical comorbidities 1.25 (0.99–1.59) 3.365 0.067 1.23 (0.97–1.57) 2.901 0.089
α-fetoprotein level (ng/mL) 1.00 (0.99–1.02) 0.037 0.847 0.98 (0.96–1.01) 1.589 0.208
Genotype of HCV (non- 1 vs. 1) 1.31 (0.59–2.92) 0.446 0.504 1.57 (0.72–3.44) 1.275 0.259
Ribavirin daily dose (g/day) 1.49 (0.40–5.59) 0.343 0.558 2.23 (0.87–5.67) 2.802 0.094
Poor treatment response (HCV RNA positive) 1.70 (0.76–3.82) 1.658 0.198 2.43 (1.09–5.41) 4.748 0.029*
Note: Group 1, patients who were treated with PegIFN-α-2a plus ribavirin; Group 2, patients who were treated with PegIFN-α-2b plus ribavirin; Depression, HADS
depression score ≥ 8; 95% CI, 95% confidence interval
*p < 0.05, **p < 0.001
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adverse effect, poor adherence to the prescription or
simply loss of follow up. The sample sizes in the two
treatment groups were small and unequal resulting cer-
tain attrition rates lead to inability for a subgroup ana-
lysis. Third, various important factors that may have
affected patients’ mental health were not identified, such
as compliance with the PegIFN-α and RBV regimen, the
presence of infectious diseases, and the taking of other
drugs (such as antidepressants). It is uncertain whether
such factors influenced the results of this study. Finally,
the assessments that were made using the HADS cov-
ered a period of one week, and do not by themselves
constitute a psychiatric diagnosis of a major depressive
disorder, which requires a depressed mood or anhedonia
with other critical associated symptoms that are present
for at least two weeks. Cut-off points of the HADS were
used to establish depression or anxiety without a formal
confirmation of the diagnosis based on DSM-IV-TR cri-
teria through a structured interview, although higher
HADS scores commonly correlate with a diagnosis of a
major depressive disorder or anxiety disorders [18].
Conclusion
This investigation did not reveal significant differences
in depression or anxiety levels of patients with chronic
hepatitis C on a 24 week antiviral treatment regimen
with PegIFN-α-2a plus RBV and those on such a corre-
sponding regiment with PegIFN-α-2b plus RBV. These
two regimens worsened HCV patients’ depression and
anxiety. Future research with larger samples and a
randomized, controlled design are warranted to verify
the findings of this study.
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